XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
he company posted total income during Q2 FY24 at Rs. 12.86 crore
European operations' revenue grew 58.4% to Rs 599.7 crore
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation
Lack of technology transfer stands out as a formidable barrier
This product will be manufactured at Lupin’s Pithampur facility in India
Aster Whitefield will be Aster's 3 rd multi-specialty hospital in Bengaluru and overall 19th hospital in India
The initiative will focus on advocating for cleaner air
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Subscribe To Our Newsletter & Stay Updated
